LAVA Therapeutics (LVTX) to Release Quarterly Earnings on Wednesday

LAVA Therapeutics (NASDAQ:LVTX) is expected to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect LAVA Therapeutics to post earnings of ($0.32) per share and revenue of $2.40 million for the quarter.

LAVA Therapeutics Price Performance

LVTX opened at $1.31 on Tuesday. The company has a market capitalization of $34.45 million, a price-to-earnings ratio of -1.27 and a beta of 0.48. The business’s 50-day moving average price is $1.07 and its two-hundred day moving average price is $1.39. LAVA Therapeutics has a 1 year low of $0.85 and a 1 year high of $4.21.

Wall Street Analyst Weigh In

Several brokerages recently commented on LVTX. Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. HC Wainwright reissued a “neutral” rating and issued a $1.50 price target (down from $2.00) on shares of LAVA Therapeutics in a report on Thursday, February 27th. Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. JMP Securities reissued a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Finally, Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat, LAVA Therapeutics currently has a consensus rating of “Hold” and an average target price of $3.17.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.